[1]
|
C. A. Jackevicius, M. M. Chou, J. S. Ross, N. D. Shah, and H. M. Krumholz, “Generic Atorvastatin and Health Care Costs,” New England Journal of Medicine, Vol. 366, No. 3, 2011, pp. 201-204. doi:10.1056/NEJMp1113112
|
[2]
|
C. Chu, E. Rudant, M. Bonvalet, H. Agostini, P. Cavalie, L. Bonhomme-Faivre, J. Frenkiel, J. Taillandier, A. Boissonnas, D. Vittecoq and B. Wyplosz, “Generic Drug Prescriptions Following Hospital Discharge: A Prospective Study in France,” European Journal of Internal Medicine, Vol. 22, No. 5, 2011, pp. e45-e49.
doi:10.1016/j.ejim.2011.01.016
|
[3]
|
M. Yamada and T. E. Welty, “Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies,” The Annals of Pharmacotherapy, Vol. 45, No. 11, 2011, pp. 1406-1415.
doi:10.1345/aph.1Q349
|
[4]
|
R. P. Shank and B. E. Maryanoff, “Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate,” CNS Neuroscience & Therapeutics, Vol. 14, No. 2, 2008, pp. 120-142.
doi:10.1111/j.1527-3458.2008.00041.x
|
[5]
|
B. A. Johnson, N. Rosenthal, J. A. Capece, F. Wiegand, L. Mao, K. Beyers, A. McKay, N. Ait-Daoud, R. F. Anton, D. A. Ciraulo, H. R. Kranzler, K. Mann, S. S. O’Malley, and R. M. Swift, “Topiramate for Treating Alcohol Dependence: A Randomized Controlled Trial,” JAMA, Vol. 298, 2007, pp. 1641-1651. doi:10.1001/jama.298.14.1641
|
[6]
|
P. Crawford, M. Feely, A. Guberman and G. Kramer, “Are There Potential Problems with Generic Substitution of Antiepileptic Drugs? A Review of Issues,” Seizure, Vol. 15, No. 3, 2006, pp. 165-176.
doi:10.1016/j.seizure.2005.12.010
|
[7]
|
J. E. Desmarais, L. Beauclair and H. C. Margolese, “Switching from Brand-Name to Generic Psychotropic Medications: A Literature Review,” CNS Neuroscience & Therapeutics, Vol. 17, No. 6, 2011, pp.750-760.
doi:10.1111/j.1755-5949.2010.00210.x
|
[8]
|
A. S. Kes-selheim, M. R. Stedman, E. J. Bubrick, J. J. Gagne, A. S. Misono, J. L. Lee, M. A. Brookhart, J. Avorn and W. H. Shrank, “Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs: A Systematic Review and Meta-Analysis,” Drugs, Vol. 70, No. 6, 2010, pp. 605-621.
doi:10.2165/10898530-000000000-00000
|
[9]
|
M. Maliepaard, N. Banishki, C. C. Gispende Wied, S. Teerenstra and A. J. Elferink, “Interchangeability of Generic Anti-Epileptic Drugs: A Quantitative Analysis of Topiramate and Gabapentin,” European Journal of Clinical Pharmacology, Vol. 67, No. 10, 2011, pp. 1007-1016. doi:10.1007/s00228-011-1041-4
|
[10]
|
L. Edvinsson and M. Linde, “New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate,” Lancet, Vol. 376, No. 9741, 2010, pp. 645-655.
doi:10.1016/S0140-6736(10)60323-6
|
[11]
|
W. E. Rosenfeld, “Topiramate: A Review of Preclinical, Pharmacoki-netic, and Clinical Data,” Clinical Therapeutics, Vol. 19, No. 6, 1997, pp. 1294-1308.
doi:10.1016/S0149-2918(97)80006-9
|
[12]
|
J. H. Park, Y. S. Park, M. H. Lee, S. Y. Rhim, J. C. Song, S. J. Lee, J. M. Kim, L. M. Shaw, and J. S. Kang, “Determination of Plasma Topiramate Concentration Using LC-MS/MS for Pharmacokinetic and Bioequivalence Studies in Healthy Korean Volunteers,” Biomedical Chromatography, Vol. 22, No. 8, 2008, pp. 822-829.
doi:10.1002/bmc.995
|
[13]
|
A. Pineyro-Lopez, E. Piney-ro-Garza, M. Gomez-Silva, R. Reyes-Araiza, M. A. Flores-Diego, S. Borrego-Alvarado, M. E. Gamino-Pena, R. Vargas-Zapata and M. E. Salazar-Leal, “Bioequivalence of Single 100-mg Doses of Two Oral Formulations of Topiramate: An Open-Label, Randomized-Sequence, Two-Period Crossover Study in Healthy Adult Male Mexican Volunteers,” Clinical Therapeutics, Vol. 31, 2009, pp. 411-417.
doi:10.1016/j.clinthera.2009.02.001
|
[14]
|
I. Saavedra, E. Tamayo, A. Gamboa, J. Sasso, N. Varela, I. Moreno, D. Marchant, D. Caceres and L. Quinones, “Relative Bioavailability Study with Two Oral Formulations of Topiramate Using a Validated UPLC-MS/MS Method,” International Journal of Clinical Pharmacology, Therapy, & Toxicology, Vol. 48, 2010, pp. 342-348.
|
[15]
|
E. Beghi, “Efficacy and Tolerability of the New Antiepileptic Drugs: Comparison of Two Recent Guidelines,” Lancet Neurology, Vol. 3, No. 10, 2004, pp. 618-621.
doi:10.1016/S1474-4422(04)00882-8
|
[16]
|
A. May, M. Leone, J. Afra, M. Linde, P. S. Sandor, S. Evers and P. J. Goadsby, “EFNS Guidelines on the Treatment of Cluster Headache and Other Trigeminal- Autonomic Cephalal-gias,” European Journal of Neurology, Vol. 13, 2006, pp. 1066-1077.
doi:10.1111/j.1468-1331.2006.01566.x
|
[17]
|
S. Evers, J. Afra, A. Frese, P. J. Goadsby, M. Linde, A. May and P. S. Sandor, “EFNS Guideline on the Drug Treatment of Migraine—Revised Report of an EFNS Task Force,” European Journal of Neurology, Vol. 16, 2009, pp. 968-981.
doi:10.1111/j.1468-1331.2009.02748.x
|